The clinical treatment of laryngeal papillomas with hematoporphyrin therapy.
Photodynamic activation of hematoporphyrin derivative was originally developed for the treatment of cancer. This article demonstrates that it may also be an effective therapy for papillomavirus infections of the larynx. Seventy-two hours prior to surgery, hematoporphyrin derivative (6 mg/kg) was given intravenously to two patients with the adult-onset form of this disease. Three days later, endoscopic surgery was performed and 32 J/cm2 was delivered to the endolarynx via an argon pump dye laser with a red light output of 630 nm. No significant complications such as swelling or hemorrhage occurred. At follow-up (13 months) there has been no recurrence of the laryngeal papilloma in either of these patients. The surgical technique, molecular biology, and clinical implications of this work to control laryngeal papillomatosis are described.
Abramson
A L
AL
Department of Otolaryngology and Communicative Disorders, Long Island Jewish Medical Center, New Hyde Park, NY 11042.
Waner
M
M
Brandsma
J
J
D000328:Adult; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006415:Hematoporphyrins / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007822:Laryngeal Neoplasms / Q000188:drug therapy*; D007828:Laryngoscopy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010212:Papilloma / Q000188:drug therapy*; D010778:Photochemotherapy; D018139:Simplexvirus / Q000235:genetics; D013997:Time Factors; D014827:Vocal Cords
D004273:DNA, Neoplasm; D006415:Hematoporphyrins